Trials Sponsors Conditions Drugs Pricing

Conditions

Brain and Central Nervous System Tumors Seizure Unspecified Adult Solid Tumor, Protocol Specific

Keywords

seizureadult tumors metastatic to brainunspecified adult solid tumor, protocol specific

Outcome Measures

Primary Outcomes (1)

Seizure control (lack of seizure activity)

Interventions

levetiracetamDrug

quality-of-life assessmentProcedure

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

DISEASE CHARACTERISTICS: * Histologically confirmed solid tumor * Pathological confirmation of brain metastasis is not required provided the clinical and neuroradiographic picture is typical * Has had at least one prior seizure due to brain metastasis PATIENT CHARACTERISTICS: * Life expectancy ≥ 12 weeks * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Absolute neutrophil count ≥ 1,500/mm³ * Platelet count ≥ 100,000/mm³ * Hemoglobin ≥ 10 g/dL * BUN \< 5 times upper limit of normal (ULN) * Creatinine \< 5 times ULN * Bilirubin \< 1.5 times ULN * AST and ALT ≤ 3 times ULN * Alkaline phosphatase ≤ 2 times ULN * No allergy to levetiracetam PRIOR CONCURRENT THERAPY: * Prior levetiracetam allowed provided it was initiated within the past 14 days * Other concurrent anticonvulsant monotherapy allowed provided therapy was initiated within the past 30 days

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Northwestern University
Otherlead
National Cancer Institute (NCI)
NIHcollaborator

MeSH Terms

Conditions

Central Nervous System NeoplasmsSeizuresBrain Neoplasms

Interventions

Levetiracetam

Condition Hierarchy (Ancestors)

Nervous System NeoplasmsNeoplasms by SiteNeoplasmsNervous System DiseasesNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsBrain DiseasesCentral Nervous System Diseases

Study Officials

Jeffrey J. Raizer, MD
Robert H. Lurie Cancer Center
PRINCIPAL INVESTIGATOR

Enrollment

0 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: not applicable
Purpose: SUPPORTIVE CARE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

December 20, 2006

First Posted

December 22, 2006

Study Start

February 2007

Date type not reported

This date has not been verified as actual or estimated.

Study Stopped

Levetiracetam in Treating Patients With Seizures Caused by Brain Metastases

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Interventions

Eligibility Criteria

Sponsors & Collaborators

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Intervention Hierarchy (Ancestors)

Source record

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Interventions

Eligibility Criteria

Sponsors & Collaborators

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Intervention Hierarchy (Ancestors)

Source record